sacituzumab govitecan-hziy for injection
sacituzumab govitecan-hziy for injection,
for intravenous use Initial U.S. Approval: 2020
Trodelvy (sacituzumab govitecan-hziy) is a medication used for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease and for patients with locally advanced or metastatic urothelial cancer (UC).
Facts about sacituzumab govitecan-hziy for injection
Disease Indications-Urothelial Carcinoma, Breast Cancer
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “sacituzumab govitecan-hziy for injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For sacituzumab govitecan-hziy for injection
Approved accessible "sacituzumab govitecan-hziy for injection"
sacituzumab govitecan-hziy for injection is a cancer medicine used to treat adults with a type of breast cancer known as triple-negative breast cancer. It is used when it is not possible to remove the cancer with surgery, because the cancer has spread to areas outside the breast (locally advanced) or to other parts of the body (metastatic ). It is used in patients who have had two or more prior systemic (whole body) treatments, including at least one of them for advanced disease.
Trodelvy contains the active substance sacituzumab govitecan.
How can 1 go about obtaining sacituzumab govitecan-hziy for injection?
To access sacituzumab govitecan-hziy for injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)
TRODELVY (sacituzumab govitecan-hziy) for injection, for intravenous use Initial U.S. Approval: 2020
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398